ReviewNature reviews. Cancer2015
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence.
Review in Nature reviews. Cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 4 registered trials, which are not on this map. Cited by 1,104 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Hypofractionated 5x5 Gy Radiotherapy With Sequential Doxorubicin and Ifosfamide-based Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall
Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors
Nitroglycerin Plus Whole Intracranial Radiotherapy for Brain Metastases in Non-small Cell Lung Cancer Patients: a Phase II Open Randomized Clinical Trial
Feasibility of a Co-designed PRe-radiotherapy Exercise Programme for People With Stage I-III Non-small Cell Lung cAnCEr: A Single-centre, Single Arm Pilot Study
Who cites it
1,104 citing papers in PubMed.
- Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415).Clinical & experimental metastasis · 2025Trial
- Article
- DNA damage in thyroid cancer patients treated with radioactive iodine in Johannesburg, South Africa.EJNMMI reports · 2026Article
- Article
- Dissociated Response to Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma Is Common and Exhibits Distinct Clinical Outcomes.Cancer research communications · 2026Article
- NNMT-associated metabolic-thromboinflammatory-immune co-activation in heterogeneous CTC clusters: a hypothesis-generating computational framework".BMC cancer · 2026Article
- Antibody-Radionuclide Conjugates for Solid Tumors: Multidimensional Strategies from Component Engineering to Synergistic Combination Therapy.International journal of molecular sciences · 2026Review
- Radiation-induced CD200Cellular & molecular immunology · 2026Article
- An Injectable Metal-Drug Supramolecular Condensate Enables Radiosensitization and Systemic Antitumor Immunity for Post-Surgical Osteosarcoma Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Association between response to gemcitabine-based neoadjuvant therapy and efficacy of gemcitabine plus nab-paclitaxel for recurrent pancreatic ductal adenocarcinoma.International journal of clinical oncology · 2026Article
- NF-κB-active tumors with matrix CAFs and suppressive immunity as key resistance mechanisms to chemoradiation in rectal cancer.Experimental & molecular medicine · 2026Article
- Real-world efficacy and safety of cemiplimab in Japanese patients with recurrent or metastatic cervical cancer: A single-center retrospective cohort study.Gynecologic oncology reports · 2026Article
- CEST-MRI assessment of locally advanced pMMR rectal cancer for prediction of immune activation status following radiotherapy.European radiology · 2026Article
- PROTAC-based nanoassemblies targeting BRD4 for potentiate FLASH radiosensitization therapy.Materials today. Bio · 2026Article
- Intra-arterial delivery of FePt nanoparticles induces ferroptosis and immune infiltration to enhance radiotherapy.Materials today. Bio · 2026Article
- TFAP2A enhances radioresistance of non-small cell lung cancer by transcriptionally activating BRCA1 : TFAP2A promotes NSCLC radioresistance.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Breast cancer radiotherapy in patients with autoimmune or cancer-associated myositis: balancing oncological benefit and immune-mediated risk.Radiation oncology (London, England) · 2026Review
- Development of Radioligand Therapy-Responsive Syngeneic Prostate Models through Murine Prostate-Specific Membrane Antigen Point Mutation.ACS pharmacology & translational science · 2026Article
- Beyond apoptosis: nanomedicine enabled reprogramming of tumor cell death for next-generation radiosensitization.Journal of nanobiotechnology · 2026Review
- The lethal symbiont: exploring the pathophysiology of cancer.Physiological reviews · 2026Review
1,044 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
Radiotherapy plays a central part in curing cancer. For decades, most research on improving treatment outcomes has focused on modulating radiation-induced biological effects on cancer cells. Recently, we have better understood that components within the tumour microenvironment have pivotal roles in determining treatment outcomes. In this Review, we describe vascular, stromal and immunological changes that are induced in the tumour microenvironment by irradiation and discuss how these changes may promote radioresistance and tumour recurrence. We also highlight how this knowledge is guiding the development of new treatment paradigms in which biologically targeted agents will be combined with radiotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.